title: [Metastatic castration-resistant prostate cancer : Clinical data, new treatment options and therapy monitoring].
abstract: Therapies currently available in Germany for metastatic castration-resistant prostate cancer (mCRPC) include docetaxel, cabazitaxel, abiraterone acetate, enzalutamide and radium-223, all of which offer a potential survival benefit that adds up in their sequential application to a significant overall survival benefit. However, the optimal sequencing of these agents is still unclear. In the absence of evidence, treatment selection is based on the particular situation and on comorbid conditions of each individual patient. Furthermore, predictive markers to facilitate the selection of patients for a specific therapy or sequence of therapies remain an unmet need. However, with the recently discovered androgen receptor splice variant V7, which mediates (cross)resistance to or between abiraterone and enzalutamide, the first such marker has been identified. It is critical to monitor the response to treatments at prespecified intervals in order to optimize treatment sequencing so that the patient does not miss a valuable therapeutic window to receive alternative treatment that may prolong his life along with good symptom control and preservation of quality of life.
authors.affiliation: Klinik für Urologie, Urologische Klinik, Charité-Universitätsmedizin Berlin, Hindenburgdamm 30, 12200, Berlin, Deutschland. kurt.miller@charite.de.
authors.forename: K
authors.initials: K
authors.lastname: Miller
authors.affiliation: Klinik für Urologie, Universitätsklinikum Düsseldorf, Düsseldorf, Deutschland.
authors.forename: P
authors.initials: P
authors.lastname: Albers
authors.affiliation: Urologikum Hamburg, Hamburg, Deutschland.
authors.forename: R
authors.initials: R
authors.lastname: Eichenauer
authors.affiliation: Urologische Praxis Berlin, Berlin, Deutschland.
authors.forename: G
authors.initials: G
authors.lastname: Geiges
authors.affiliation: Urologische Klinik, Universitätsklinikum Jena, Jena, Deutschland.
authors.forename: M-O
authors.initials: MO
authors.lastname: Grimm
authors.affiliation: Aturo Urologische Praxis Berlin, Berlin, Deutschland.
authors.forename: F
authors.initials: F
authors.lastname: König
authors.affiliation: Centrum für Operative Urologie Bremen, Bremen, Deutschland.
authors.forename: G
authors.initials: G
authors.lastname: Mickisch
authors.affiliation: Klinik und Poliklinik für Urologie, Uniklinik Köln, Köln, Deutschland.
authors.forename: D
authors.initials: D
authors.lastname: Pfister
authors.affiliation: Urologische Klinik, Diakonie-Klinikum Stuttgart, Stuttgart, Deutschland.
authors.forename: C
authors.initials: C
authors.lastname: Schwentner
authors.affiliation: Urologikum Hamburg, Hamburg, Deutschland.
authors.forename: H
authors.initials: H
authors.lastname: Suttmann
authors.affiliation: Klinik und Poliklinik für Urologie, Universitätsklinikum Dresden, Dresden, Deutschland.
authors.forename: S
authors.initials: S
authors.lastname: Zastrow
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D014408:Biomarkers, Tumor / Q000097:blood*; D004334:Drug Administration Schedule; D016903:Drug Monitoring / Q000379:methods*; D019317:Evidence-Based Medicine; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D064129:Prostatic Neoplasms, Castration-Resistant / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor
keywords: Abiraterone; Cabazitaxel; Castration-resistant prostate cancer; Docetaxel; Enzalutamide